KBC Group NV Boosts Stock Position in Tilray Inc (NASDAQ:TLRY)

KBC Group NV raised its holdings in Tilray Inc (NASDAQ:TLRYFree Report) by 75.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,332 shares of the company’s stock after buying an additional 16,539 shares during the period. KBC Group NV’s holdings in Tilray were worth $51,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in shares of Tilray by 1,314.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company’s stock worth $3,202,000 after acquiring an additional 1,690,827 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Tilray in the third quarter valued at approximately $1,348,000. XTX Topco Ltd increased its stake in Tilray by 1,079.7% in the third quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock valued at $495,000 after purchasing an additional 257,641 shares during the last quarter. Barclays PLC raised its holdings in Tilray by 600.4% during the third quarter. Barclays PLC now owns 204,144 shares of the company’s stock worth $359,000 after purchasing an additional 174,997 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Tilray by 6.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,677,899 shares of the company’s stock worth $2,953,000 after buying an additional 107,530 shares during the last quarter. 9.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Canaccord Genuity Group increased their target price on shares of Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $2.70.

Get Our Latest Stock Report on Tilray

Insider Activity at Tilray

In other news, CFO Carl A. Merton bought 26,000 shares of Tilray stock in a transaction dated Friday, November 15th. The stock was bought at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the purchase, the chief financial officer now owns 26,000 shares of the company’s stock, valued at approximately $35,360. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.87% of the stock is currently owned by insiders.

Tilray Trading Down 2.0 %

TLRY opened at $0.98 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 2.54 and a debt-to-equity ratio of 0.10. Tilray Inc has a 52 week low of $0.94 and a 52 week high of $2.97. The business’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.52. The firm has a market cap of $919.37 million, a price-to-earnings ratio of -3.27 and a beta of 2.07.

Tilray (NASDAQ:TLRYGet Free Report) last announced its earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07). Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. The business had revenue of $210.90 million for the quarter, compared to analysts’ expectations of $216.34 million. The business’s revenue was up 8.7% compared to the same quarter last year. On average, research analysts predict that Tilray Inc will post -0.2 EPS for the current year.

Tilray Company Profile

(Free Report)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.

Further Reading

Institutional Ownership by Quarter for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.